Correction: Alhajlah et al. Overexpression of Reticulon 3 Enhances CNS Axon Regeneration and Functional Recovery After Traumatic Injury. Cells 2021, 10, 2015

In the original manuscript [1], there was a mistake in Figure 8 as published. In the original Figure 8G, the ONC+shEGFP and ONC+RTN3+shProtrudin panels were similar to the PBS and PEDF panels of another published article [2]. When compiling the figure, the wrong raw image was copied over from the storage device and used in the figure. The corrected Figure 8 appears below.

Figure 8.

RTN3 overexpression promotes RGC axon regeneration and functional recovery after ONC, which is also protrudin-dependent. (A) Western blot and (B) quantification to show that RTN3 plasmids significantly upregulate RTN3 protein in the retina after intravitreal injection in vivo. (C) Immunohistochemistry to localise RTN3 protein to the RGCs (green) in the ganglion cell layer (GCL) and the inner plexiform and inner nuclear layer (INL). ONL = outer nuclear layer. (D) High power images to show RTN3 protein localised to βIII-tubulin⁺ RGCs (white arrows) in the GCL. (E) GAP43 immunohistochemistry (* = lesion site) and (F) quantification to show that in control optic nerve, few, if any, GAP43⁺ axons pass beyond the lesion site, whilst in RTN3 overexpressed eyes, significant GAP43⁺ axons are present beyond the lesion site, an effect which is obliterated when Protrudin is knocked out at the same time as RTN3 overexpression. (G) Representative images to show FluorGold (FG) backfilled RGC in retinal wholemounts after RTN3 overexpression. (H) Quantification of the number of FG⁺ RGC in retinal wholemounts shows that overexpression of RTN3 is significantly neuroprotective, an effect that is independent of protrudin. (I) Representative ERG traces and (J) quantification of the pSTR amplitude show significant improvements in RTN3 overexpressed eyes, which are ablated after protrudin knockdown. Black arrows show the peak of the pSTR. Data are means ± SEM. n = 12 eyes/optic nerves/treatment. Scale bars in (C) = 100 µm, scale bars in (D) = 25 µm, scale bars in (E) = 200 µm, scale bars in (G) = 50 µm. *** p = 0.0001, one-way ANOVA with Dunnett’s post hoc test.

Additionally, the Conflicts of Interest statement was updated for full transparency. The corrected statement is below.

Conflicts of Interest

Zubair Ahmed was a co-founder and co-owner of Neuregenix Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest. The funding sponsors had no role in the design of the study; in the collection, analysis, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.